Search

  6. ProQR Announces First Patient Dosed in Phase 1/2 Aurora Trial of QR-1123 for Autosomal Dominant Retinitis Pigmentosa

    Press release

    … to changing lives through the creation of transformative RNA medicines for severe genetic rare diseases, today … in 2021. “From previous clinical trials we have seen that RNA therapies can be a promising approach for patients with … excited to have started a clinical trial for the third RNA therapy in our inherited retinal disease pipeline.” About the …

  7. ProQR Doses First Patient in Phase 2/3 ILLUMINATE Trial of Sepofarsen for LCA10

    Press release

    … to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare … lead to blindness in early childhood. No form of therapy is currently available,” said Dr. Katarina Stingl of … Tübingen, Investigator in the ILLUMINATE trial. “ProQR’s RNA therapy for the p.Cys998X mutation showed the potential …

  8. ProQR Doses First Patient in Phase 1/2 STELLAR Trial of QR-421a for Usher Syndrome Type 2

    Press release

    … to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare … first studies of its kind exploring the impact of ProQR’s RNA therapies on patients with Usher syndrome due to an Exon … STELLAR trial will explore whether QR-421a (ProQR’s RNA therapy) can slow disease progression or even reverse it. …